Effects of Endocrine Therapy on Cardiovascular Diseases and Type 2 Diabetes Among Breast Cancer Survivors: The National Health Insurance Service Database of Korea
Ji‐Eun Kim,Jaesung Choi,JooYong Park,Wonshik Han,Daehee Kang,Ji‐Yeob Choi
DOI: https://doi.org/10.1161/JAHA.122.026743
2022-10-18
Abstract:Background Although endocrine therapy is an effective treatment for breast cancer, its antiestrogen effects are associated with increased risks of cardiovascular diseases and type 2 diabetes. This study aimed to investigate the association between endocrine therapy and the risk of cardiovascular diseases and type 2 diabetes among breast cancer survivors in Korea, in consideration of various age groups. Methods and Results In the National Health Insurance Service database of Korea, a total of 133 171 patients with breast cancer aged ≥20 years were included in the current study. Endocrine therapy was treated as time‐varying exposure, and patients were categorized as nonusers, selective estrogen receptor modulator users, aromatase inhibitor users, and both users. Time‐dependent Cox regression models were used to estimate hazard ratios (HRs) and 95% CIs. Age at diagnosis, socioeconomic status, histological type, other treatments, and comorbidities were adjusted in the model. Compared with nonusers, selective estrogen receptor modulator users were associated with higher risks of stroke (HR, 1.20 [95% CI, 1.04–1.40]) and venous thromboembolism (HR, 1.47 [95% CI, 1.13–1.90]), whereas aromatase inhibitor users were associated with a higher risk of coronary heart disease (HR, 1.22 [95% CI, 1.06–1.41]). The risk of type 2 diabetes was associated with selective estrogen receptor modulator users (HR, 1.13 [95% CI, 1.05–1.21]), aromatase inhibitor users (HR, 1.14 [95% CI, 1.05–1.23]), and both users (HR, 1.24 [95% CI, 1.10–1.39]). In particular, the risk of a composite of cardiovascular diseases was higher in younger or premenopausal patients. Conclusions In breast cancer survivors in Korea, endocrine therapy is associated with a higher risk of cardiovascular diseases and type 2 diabetes. Monitoring of cancer comorbidities after endocrine therapy is needed in younger and older patients. Nonstandard Abbreviations and Acronyms AI aromatase inhibitor NHIS National Health Insurance Service PSM propensity score matching SERM selective estrogen receptor modulator T2D type 2 diabetes Clinical Perspective What Is New? As a large, longitudinal, population‐based study of Korea (N=133 171), endocrine therapy was associated with elevated risks of a composite of cardiovascular diseases and type 2 diabetes in patients with breast cancer diagnosed from 2006 to 2016. The increased risk of cardiovascular diseases could be affected by menopausal status and the age of diagnosis among patients with breast cancer, whereas the risk of type 2 diabetes was higher regardless of age. What Are the Clinical Implications? It is necessary to manage cancer comorbidities in younger endocrine therapy users, as well as in older breast cancer survivors. Monitoring of cancer comorbidities after endocrine therapy in various age groups may contribute to the healthy prognosis of patients with breast cancer. Breast cancer is the most commonly diagnosed cancer in women, and its prevalence is steadily increasing worldwide. 1 , 2 The incidence of breast cancer in Korea continues to increase across all age groups. Some of the key features of breast cancer in Korea are its higher incidence in younger women aged 40 to 49 years, an increasing proportion of premenopausal women, and a higher survival rate than in other countries. Improved cancer screening and advanced cancer treatment will further increase the number of breast cancer survivors. 2 It has been reported that many breast cancer survivors die from noncancer diseases, especially cardiovascular disease (CVD) and diabetes, rather than their diagnosed cancer. 3 , 4 This is likely to be affected by common risk factors (such as age, alcohol intake, tobacco use, obesity, physical activity, diet, and adverse events caused by cancer treatment) between breast cancer and other non‐communicable diseases. 5 Endocrine therapies used for hormone receptor‐positive patients with breast cancer are classified as selective es -Abstract Truncated-